RCE Stock Overview
Recce Pharmaceuticals Ltd, discovers, develops, and commercializes synthetic anti–infectives in Australia, the United Kingdom, and the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Recce Pharmaceuticals Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.47 |
| 52 Week High | AU$0.69 |
| 52 Week Low | AU$0.38 |
| Beta | 1.13 |
| 11 Month Change | -12.96% |
| 3 Month Change | -4.08% |
| 1 Year Change | 6.82% |
| 33 Year Change | -43.71% |
| 5 Year Change | 88.00% |
| Change since IPO | 56.67% |
Recent News & Updates
Recent updates
We Think Shareholders Are Less Likely To Approve A Pay Rise For Recce Pharmaceuticals Ltd's (ASX:RCE) CEO For Now
Nov 01
Here's Why We're Watching Recce Pharmaceuticals' (ASX:RCE) Cash Burn Situation
Feb 13We're Hopeful That Recce Pharmaceuticals (ASX:RCE) Will Use Its Cash Wisely
Jul 28Recce Pharmaceuticals (ASX:RCE) Is In A Good Position To Deliver On Growth Plans
Dec 07We're Hopeful That Recce Pharmaceuticals (ASX:RCE) Will Use Its Cash Wisely
Aug 03Recce Pharmaceuticals (ASX:RCE) Is In A Good Position To Deliver On Growth Plans
Mar 08Need To Know: Recce Pharmaceuticals Ltd (ASX:RCE) Insiders Have Been Selling Shares
Feb 01Could The Recce Pharmaceuticals Ltd (ASX:RCE) Ownership Structure Tell Us Something Useful?
Dec 09Shareholder Returns
| RCE | AU Pharmaceuticals | AU Market | |
|---|---|---|---|
| 7D | -6.0% | -11.8% | 1.5% |
| 1Y | 6.8% | 39.8% | 17.2% |
Return vs Industry: RCE underperformed the Australian Pharmaceuticals industry which returned 39.8% over the past year.
Return vs Market: RCE underperformed the Australian Market which returned 17.2% over the past year.
Price Volatility
| RCE volatility | |
|---|---|
| RCE Average Weekly Movement | 6.7% |
| Pharmaceuticals Industry Average Movement | 11.9% |
| Market Average Movement | 8.6% |
| 10% most volatile stocks in AU Market | 17.3% |
| 10% least volatile stocks in AU Market | 3.4% |
Stable Share Price: RCE has not had significant price volatility in the past 3 months compared to the Australian market.
Volatility Over Time: RCE's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | n/a | James Graham | www.recce.com.au |
Recce Pharmaceuticals Ltd, discovers, develops, and commercializes synthetic anti–infectives in Australia, the United Kingdom, and the United States. Its lead candidate is RECCE 327 (R327) for the treatment of blood infections and sepsis derived from E. coli and S. aureus bacteria, including their superbug forms. The company also develops RECCE 529, a synthetic anti-infective for viral infections; and RECCE 435, a synthetic polymer antibiotic formulated for oral use.
Recce Pharmaceuticals Ltd Fundamentals Summary
| RCE fundamental statistics | |
|---|---|
| Market cap | AU$106.66m |
| Earnings (TTM) | -AU$17.66m |
| Revenue (TTM) | AU$5.03m |
21.7x
P/S Ratio-6.2x
P/E RatioIs RCE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RCE income statement (TTM) | |
|---|---|
| Revenue | AU$5.03m |
| Cost of Revenue | AU$7.22m |
| Gross Profit | -AU$2.19m |
| Other Expenses | AU$15.47m |
| Earnings | -AU$17.66m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.076 |
| Gross Margin | -43.52% |
| Net Profit Margin | -351.24% |
| Debt/Equity Ratio | -101.7% |
How did RCE perform over the long term?
See historical performance and comparison